BRD ELISA Kits

BRD (Bromodomain-containing protein) ELISA Kits are immunoassays specifically developed for the quantification of BRD family proteins in various biological samples. Bromodomain-containing proteins, such as BRD2, BRD3, and BRD4, are epigenetic readers that recognize acetylated lysine residues on histones, playing a key role in gene transcription regulation. They are highly significant in research on transcriptional control, inflammation, cancer, and other diseases where gene expression regulation is altered. By using antibodies that precisely target specific BRD proteins, these kits enable sensitive and reproducible quantification.

Content

BRD ELISA Kits generally include:

• Microplates pre-coated with capture antibodies specific to targeted BRD family proteins.
• Detection antibodies conjugated to enzymes, such as horseradish peroxidase (HRP), for chromogenic or fluorometric detection.
• Standards and controls to allow for quantifiable and reproducible measurements across sample batches.
• Buffers and reagents including wash, blocking, and substrate solutions to enhance assay performance and reduce background noise.

The assay involves binding the BRD protein from the sample to the capture antibody on the microplate, followed by detection with the enzyme-labeled secondary antibody. The resulting signal, proportional to BRD concentration, is measured to determine the BRD levels in the sample.

Applications

BRD ELISA Kits are instrumental in:

• Epigenetics and transcription research: Quantifying BRD protein levels in studies focused on transcriptional regulation and chromatin remodeling.
• Cancer research: Evaluating BRD expression, as many BRD proteins are implicated in cancer due to their role in transcriptional regulation and cell proliferation.
• Drug discovery and pharmacology: Screening potential BRD inhibitors, especially BRD4 inhibitors, which are being studied as anti-cancer and anti-inflammatory drugs.

BRD ELISA Kits provide a standardized and sensitive method for measuring BRD proteins, aiding in understanding transcription regulation, epigenetic modifications, and the development of targeted therapies in diseases with BRD involvement.